TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis C$14.90 -0.20 (-1.32%) As of 09/3/2025 Add Compare Share Share Stock Analysis Stock Analysis About Oncolytics Biotech Stock (TSE:ONC) Get Oncolytics Biotech alerts:Sign Up Key Stats Today's RangeC$14.90▼C$14.9050-Day RangeC$14.90▼C$14.9052-Week RangeC$0.44▼C$2.08Volume280 shsAverage Volume169,589 shsMarket CapitalizationC$1.50 billionP/E RatioN/ADividend Yield0.31%Price TargetN/AConsensus RatingN/A Company Overview Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Read More Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONC Stock News HeadlinesOncolytics Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14, 2026 | marketscreener.comMOncolytics Biotech, Coherus Sign Clinical Supply Agreement for Pelareorep StudyNovember 11, 2026 | marketscreener.comMDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)Oncolytics Biotech Inc. Presents Translational Data From Phase 1b/2 Trial Of Pelareorep In Relapsed/Refractory Multiple MyelomaNovember 10, 2026 | marketscreener.comMOncolytics Biotech Inc. Reports Translational Data from Anal Cancer Patients Demonstrating Pelareorep Drives Hpv-Specific Immune ResponsesNovember 5, 2026 | marketscreener.comMOncolytics Biotech Inc Announces Updated Data From Cohort 4 of Phase 1/2 GOBLET Study Evaluating Pelareorep in Combination With Atezolizumab in Patients With Second-Line or ...October 27, 2026 | marketscreener.comMOncolytics Biotech Inc. reports updated clinical data from cohort 4 of GOBLET studyOctober 27, 2026 | msn.comOncolytics Biotech Inc. Provides Update On GOBLET Phase 1/2 Study Clinical DataOctober 15, 2026 | marketscreener.comMSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncolytics Biotech's stock was trading at C$14.90 at the beginning of 2026. Since then, ONC stock has increased by 0.0% and is now trading at C$14.90. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) announced its quarterly earnings data on Tuesday, November, 12th. The company reported C($0.12) earnings per share for the quarter, missing the consensus estimate of C($0.11) by C$0.01. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Sorrento Therapeutics (SRNE), Enbridge (ENB), Organigram (OGI), ProMetic Life Sciences (PLI), Air Canada (AC) and BlackBerry (BB). Industry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolTSE:ONC CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$27.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-189.05% Return on Assets-71.33% Debt Debt-to-Equity Ratio17.78 Current Ratio2.82 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$3.53 per share Price / Cash Flow4.22 Book ValueC$0.08 per share Price / Book190.47Miscellaneous Outstanding Shares100,361,000Free FloatN/AMarket CapC$1.50 billion OptionableNot Optionable Beta0.80 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (TSE:ONC) was last updated on 9/3/2025 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.